All lobbying filings

ELI LILLY AND COMPANY

ELI LILLY AND COMPANY filed a Q4 report for ELI LILLY AND COMPANY on January 15, 2026.

Lobbying for ELI LILLY AND COMPANY

All filings by ELI LILLY AND COMPANY · Everything ELI LILLY AND COMPANY has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 15, 2026

Expenses

$2,200,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 5

SARAH KYLE

Previously held: Legislative Asst, Senator Bayh (2007-2011); Legislative Asst, Rep Tim Roemer (2000-2003)
THOMAS CORDREY ROBERGE JR

Previously held: Legislative Counsel (2002-2004 - Senator Peter Fitzgerald)
ASKIA SURUMA

Previously held: Chief of Staff, Rep. Marc Veasey (2017-2021); Deputy Staff Director, Ways and Means Committee (2007-2014); Deputy Staff Director, House Rules Committee (2001-2007); Legislative Director, Rep. Martin Frost (2000-2001)
SHANNON STEHOUWER

Previously held: Staff, Senator John Hoeven (2014-2016); Staff, Rep. Mike Rogers (2010-2014)
JUAN MACHADO

Previously held: Senate Finance Committee; Professional Staff and Senior Health Advisor, Department of Health & Human Services, Health Insurance Specialist

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 8

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 7

Trade (domestic/foreign)

Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs

Health Issues

Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)

Medicare/Medicaid

Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)

Consumer Issues/Safety/Products

Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality

Pharmaceutical intellectual property issues

Taxation/Internal Revenue Code

Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)

Pharmacy

Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act

Bills named in this filing 2

H.R. 5376
Impacts and Outcomes for Health Career Training Act
H.R. 1
Lower Energy Costs Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.